MedTrace Logo

Evaluating the Effectiveness of Ondansetron Versus Dexamethasone Versus Placebo for the Control of Intraoperative Nausea and Vomiting in Patients Undergoing Lower-segment Caesarean Section Under Spinal Anesthesia

NCT05583214 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-10-18

No results posted yet for this study

Summary

The goal of this randomized controlled trial is to evaluate the effectiveness of Ondansetron, Dexamethasone, and Placebo for intraoperative nausea and vomiting in patients undergoing caesarian section under spinal anesthesia. The main question it aims to answer are:

Which drug is the best at reducing the incidence of intraoperative nausea and vomiting.

Which drug is the best at reducing intraoperative pain.

Participants will be randomly divided into three groups, each will be given a different drug labelled A, B, or C.

A rating scale will be used to evaluate the severity of intraoperative nausea and pain. Episodes of vomiting will be recorded.

Data collected from the three groups will be analyzed using SPSS software.

Conditions

  • Caesarean Section
  • Spinal Anesthesia

Interventions

DRUG

Ondansetron 8mg

8mg of Ondansetron IV stat will be given to the group after induction of spinal anesthesia

DRUG

Dexamethasone 8mg

8mg of Dexamethasone IV stat will be given to the group after induction of spinal anesthesia

DRUG

Normal saline

Normal saline will be given IV stat to the group after induction of spinal anesthesia

Sponsors & Collaborators

  • Muhammad Mubariz

    lead OTHER

Principal Investigators

  • Muhammad Mubariz, MBBS · House Officer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-31
Primary Completion
2022-12-31
Completion
2023-01-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05583214 on ClinicalTrials.gov